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Dear Editor,
The epidemiology of Candida species-associated invasive fungal
infections is evolving, and many uncommon Candida species have
recently emerged as etiologic agents of bloodstream and other invasive
infections. This emergence is attributable to the use of antifungal
drugs, such as azoles, for prophylaxis and echinocandins among high-
risk populations. Notably, these species exhibit decreased in vitro
susceptibility to the antifungals used for therapy.1 In the last few years,
clinical treatment failures for Candida haemulonii infections associated
with resistance to amphotericin B (AMB) and reduced susceptibility to
azoles and echinocandins have been reported.2–4 Members of the
Candida haemulonii species complex are uncommon yeasts that cause
bloodstream and deep-seated infections, and consist of two genotypi-
cally distinguishable species, that is, C. haemulonii and C. duobush-
aemulonii, and a variety, C. haemulonii var. vulnera.2 These species and
other relatives of C. haemulonii, that is, Candida auris and Candida
pseudohaemulonii, cannot be differentiated by the commercial yeast
identiﬁcation methods used in microbiology laboratories; thus, the
true distributions of C. haemulonii and sibling species remain
unknown.5
Although the prevalence of uncommon Candida species vary
geographically, infections due to C. haemulonii are primarily reported
in South America, Asia, the Middle East and Europe.2–8 Despite their
emergence as opportunistic yeasts in several countries, there is a
paucity of data regarding the genetically related C. haemulonii species
complex from clinical sources. In addition, unlike its sibling species,
C. auris, which is known for clonal endemicity in hospitals, no
information regarding the genetic diversity of the C. haemulonii
species complex is available.5 Herein, we describe the emergence of
the C. haemulonii species complex in three hospitals in India.
Furthermore, multilocus phylogenetic analyses were performed to
investigate the species/varieties in the clinical C. haemulonii species
complex, and ampliﬁed fragment-length polymorphism (AFLP)
ﬁngerprinting was applied to determine their genetic diversity. AFLP
was ﬁrst described 20 years ago and is known to have high
discriminatory power due to the generation of many informative
genetic markers.9 In addition, the antifungal susceptibility proﬁle of
the C. haemulonii species complex was determined.
Clinical isolates were collected from 2010 to 2015 from individual
patients in two tertiary care hospitals in Delhi and a solitary hospital in
Kochi, Kerala, in South India. The isolates were presumptively
identiﬁed as C. haemulonii with the VITEK2 system (Biomerieux,
Marcy l'Etoile, France) in local hospitals. However, matrix-assisted
laser desorption ionization–time-of-ﬂight mass spectrometry
(MALDI–TOF MS; Bruker-Daltonics, Bremen, Germany) accurately
identiﬁed the species and variety in the C. haemulonii species complex.
These species included C. duobushaemulonii (n= 8), C. haemulonii
(n= 6) and C. haemulonii var. vulnera (n= 1). The species’ morphol-
ogies were studied on Sabouraud dextrose agar, CHROMagar Candida
medium (Becton-Dickinson, Baltimore, MI, USA) and rice Tween-80
agar, and their growth characteristics were examined at 37 °C and 42 °C.
Antifungal susceptibility testing with ﬂuconazole (FLU), itraconazole
(ITC), voriconazole (VRC), isavuconazole (ISAV), posaconazole
(POS), AMB, 5-ﬂucytosine (FC), caspofungin (CAS), micafungin
(MFG) and anidulafungin (AFG) was performed using both the
M27-A3 Clinical and Laboratory Standards Institute (CLSI) broth
microdilution method10 and the AST-YS07 card of the VITEK2.
Furthermore, to determine the multilocus phylogeny, four loci,
including the internal transcribed spacer region (ITS), D1/D2, RPB1
and RPB2, were sequenced.2 A neighbor-joining (NJ) phylogenetic tree
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based on the concatenated sequences of the four loci was constructed
using MEGA version 6 (http://www.megasoftware.net/). In addition,
as previously described, an AFLP dendrogram was generated with
Bionumerics v6.6 (Applied-Maths, Sint-Martens-Latem, Belgium)
using the standard Pearson and unweighted pair group method with
averages (UPGMA).11
GenBank BLAST searches of the ITS region and MALDI–TOF MS
conﬁrmed the presence of 15 isolates belonging to C. duobushaemulonii
(n= 8), C. haemulonii (n= 6) and C. haemulonii var. vulnera (n= 1).
The ITS sequences of all of the isolates exhibited 100% homologies with
the type and reference strains of the respective species in GenBank. The
isolates originated from the deep-seated tissue or bone obtained during
surgical debridement (n= 9), blood (n= 5) and BAL (n= 1). The
isolates exhibited budding yeast cells with pseudohyphae and developed
a dark pink color in CHROMagar Candida medium after 48 h of
incubation at 37 °C. The isolates grew well at 37 °C, whereas no growth
was observed at 42 °C. The NJ tree consisted of three major clades
(Figure 1). Clades 1 and 2 contained C. haemulonii (n= 3 each) and a
solitary C. haemulonii var. vulnera isolate in addition to the type and
reference strains, and suggested strain variation. The similarity percen-
tages among the C. haemulonii isolates were 79%–89%. However, all of
the C. duobushaemulonii clustered together in clade 3. Notably, and as
previously reported, the currently available loci (ITS, LSU, RPB1 and
RPB2) possessed low discriminatory power for describing the intra-
species genetic diversity of C. haemulonii, C. haemulonii var. vulnera and
C. duobushaemulonii.2 Thus, the inclusion of better polymorphic genes
for multilocus sequence analysis is warranted for investigations of the
clonal transmissions of these species. The AFLP ﬁngerprint analysis
revealed markedly variable banding patterns with ~ 50 bands/strain
comprising 25–425 bp overall.
High geometric mean (GM) minimum inhibitory concentrations
(MICs) for FLU (CLSI 12.7 mg/L; VITEK2 24.2 mg/L) and
AMB (CLSI 14.6 mg/L; VITEK2 6.6 mg/L) were observed via both
the CLSI and VITEK2 methods. In contrast, all isolates exhibited low
CLSI GM MICs for ISA (0.02 mg/L), POS (0.08 mg/L), ITC (0.3 mg/
L) and VRC (0.134 mg/L) with the exception of a solitary C.
haemulonii isolate that exhibited a high MIC for VRC (4 mg/L).
Notably, a signiﬁcant twofold greater CLSI MIC for FLU was observed
for C. haemulonii (GM 26.2 mg/L) than for C. duobushaemulonii (GM
6.72 mg/L; Supplementary Table S1). In addition, all of the isolates
exhibited low GM MICs for CAS (CLSI 0.15 mg/L; VITEK2 0.30 mg/L),
MFG (CLSI 0.33 mg/L; VITEK2 0.10 mg/L) and AFG (CLSI 0.5 mg/L),
with the exception being solitary isolates of C. haemulonii var. vulnera
and C. duobushaemulonii, which exhibited high MICs (1 mg/L) against
all of the echinocandins and high MICs (1 mg/L) for AFG and MFG,
respectively, by CLSI. Furthermore, signiﬁcantly lower (Mann-Whitney
Po0.05) GM MICs for VRC, CAS and FC, and higher GM MICs for
AMB and MFG were observed by CLSI compared with VITEK2.
However, the two methods exhibited good agreement (80%–100%)
for AMB, FLU, CAS and MFG, but a low agreement (20%) was noted
for VRC. Therefore, standardization of VITEK2 via testing with a
larger number of C. haemulonii isolates is warranted to validate the use
of the VITEK2 system as an alternative method for routine use in
laboratories for susceptibility testing.
The clinical features and outcomes of the 15 patients were retrieved
from records (Supplementary Table S2). Nine patients had chronic
foot infections, and surgically debrided bone and soft tissues yielded
C. haemulonii isolates that included C. haemulonii var. vulnera in ﬁve
patients and C. duobushaemulonii in four. All nine patients had the
major risk factor of uncontrolled diabetes and underwent foot
amputations. Two of the nine patients also received azole antifungals.
Figure 1 (A) Neighbor-joining phylogenetic tree based on the ITS, D1/D2, RPB1 and RPB2 sequences with 2000 bootstrap replications using MEGA version 6.
(B) AFLP dendrogram using UPGMA in combination with the Pearson correlation coefﬁcients of the Candida haemulonii species complex and the reference
strains (C. duobushaemulonii CBS9754, CBS7799 and CBS7798T; C. haemulonii CBS7801 and CBS7802; and C. pseudohaemulonii CBS 10004T and
KCTC17807). The scale bar indicates the percentage similarity. ampliﬁed fragment-length polymorphism, AFLP; internal transcribed spacer region, ITS;
unweighted pair group method with averages, UPGMA.
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Among the ﬁve candidemia patients, two had acute myeloid leukemia
and the remaining three patients had the underlying conditions of
renal transplant and abdominal surgery. Breakthrough candidemia
while on azole prophylaxis (FLU= 3 and VRC= 1) was noted in four
patients. VRC therapy was initiated in three candidemia patients and
two were successfully managed. The 28-day all-cause mortality among
the candidemia patients was 60%. Overall, the patients had at least
three predisposing risk factors for candidiasis as previously reported,12
and these risk factors included the following: 15 (100%) were on
broad-spectrum antibiotics, ten (66%) had diabetes mellitus, six
(40%) had chronic kidney conditions, ﬁve (33.3%) had coronary
artery disease, four (27%) had peripheral occlusive vascular disease,
three (20%) had malignancies, two (13%) had undergone renal
transplant and one had undergone abdominal surgery.
Worldwide, the uncommon Candida species that cause infections
are not well characterized.1,13 The present study reports the large series
of candidiasis cases due to the C. haemulonii species complex with
clinical and microbiological data that provide novel insights into this
yeast. Unlike its sibling species, C. auris, which is widely prevalent in
Indian hospitals, C. haemulonii accounts for only 0.8% of Candida
species. Notably, previous reports regarding the occurrence of
C. haemulonii in India are misleading because the identiﬁcations were
performed with conventional or commercial identiﬁcation systems.14
Recently, Kathuria et al.15 reported that of 102 C. haemulonii isolates
identiﬁed with the VITEK2 system in ﬁve centers in India, 88.2%
(n= 90) were subsequently conﬁrmed as C. auris by ITS sequencing.
Notably, a high frequency of infections due to the C. haemulonii
species complex was observed in the patients with diabetes mellitus
(66.6%). Furthermore, as previously reported, the C. haemulonii
isolates exhibited elevated MICs to AMB and FLU.2,3 In addition,
the high MICs to echinocandins noted in two isolates (C. haemulonii
var. vulnera and C. duobushaemulonii) are worrisome. Thus far, two
previous studies have reported high MICs for echinocandins.2,4 In
conclusion, this study highlights the signiﬁcance of C. haemulonii
species in chronic foot infections and candidemia, and the cases of the
latter were associated with breakthrough infections, speciﬁcally in the
patients on FLU therapy. Thus, correct identiﬁcations and determina-
tions of the antifungal susceptibilities of C. haemulonii isolates are
warranted to guide antifungal therapy. Because the clinical experience
with C. haemulonii infections is limited, optimal treatments have not
yet been deﬁned.16 However, the in vitro activities of VRC, POS and
ISAV suggest that they can be used as effective treatment options.
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